AT845 ( DrugBank: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
256 | 筋型糖原病 | 2 |
256. 筋型糖原病
臨床試験数 : 180 / 薬物数 : 133 - (DrugBank : 29) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 105
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2019-003595-38-GB (EUCTR) | 20/11/2020 | 03/07/2020 | FORTIS: AAV8-Delivered Gene Therapy in Late Onset Pompe Disease | FORTIS: A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients with Late Onset Pompe Disease - FORTIS | Late Onset Pompe Disease MedDRA version: 20.1;Level: PT;Classification code 10053185;Term: Glycogen storage disease type II;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: AT845 Product Code: AT845 | Audentes Therapeutics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 8 | Phase 1;Phase 2 | Germany;Italy;United Kingdom | ||
2 | NCT04174105 (ClinicalTrials.gov) | October 27, 2020 | 13/11/2019 | Gene Transfer Study in Patients With Late Onset Pompe Disease | A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease | Pompe Disease (Late-onset) | Genetic: AT845 | Astellas Gene Therapies | NULL | Recruiting | 18 Years | 80 Years | All | 12 | Phase 1/Phase 2 | United States;United Kingdom;Germany |